Prolactinomas

Schmidek and Sweet Operative Neurosurgical Techniques: Indications, Methods, and Results: Sixth Edition

Volumn 1, Issue , 2012, Pages 221-227

  Liu, James K ^a   Krieger, Mark D ^b   Amar, Arun P ^b   Couldwell, William T ^c   Weiss, Martin H ^b  

^a New Jersey Medical School   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902034719     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6839-6.10019-X     Document Type: Chapter

References (139)

1. Wang M.Y., Weiss M.H. Is there a role for surgery for microprolactinomas?. Semin Neurosurg 2001, 12:289-294.
2. Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009, 23:575-596.
3. Vance M.L., Thorner M.O. Prolactinomas. Endocrinol Metab Clin North Am 1987, 16:731-753.
4. Nomikos P., Buchfelder M., Fahlbusch R. Current management of prolactinomas. J Neurooncol 2001, 54:139-150.
5. Colao A., Di Sarno A., Cappabianca P., et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003, 349:2023-2033.
6. Ezzat S., Asa S.L., Couldwell W.T., et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004, 101:613-619.
7. Bevan J.S., Webster J., Burke C.W., et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992, 13:220-240.
8. Vance M.L., Evans W.S., Thorner M.O. Drugs five years later. Bromocriptine. Ann Intern Med 1984, 100:78-91.
9. Molitch M.E. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002, 5:55-65.
10. Molitch M.E. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999, 28:143-169. vii.
11. Amar A.P., Couldwell W.T., Chen J.C., et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 2002, 97:307-314.
12. Couldwell W.T., Rovit R.L., Weiss M.H. Role of surgery in the treatment of microprolactinomas. Neurosurg Clin North Am 2003, 14:89-92. vii.
13. Blackwell Hyperprolactinemia R.E. Evaluation and management. Endocrinol Metab Clin North Am 1992, 21:105-124.
14. Biller B.M. Diagnostic evaluation of hyperprolactinemia. J Reprod Med 1999, 44:1095-1099.
15. Pituitary adenomas and oral contraceptives: a multicenter case-control study. Fertil Steril 1983, 39:753-760. Pituitary Adenoma Study Group.
16. Weiss M. Pituitary tumors: an endocrinological and neurosurgical challenge. Clin Neurosurg 1992, 39:114-122.
17. Franks S., Murray M.A., Jequier A.M., et al. Incidence and significance of hyperprolactinaemia in women with amenorrhea. Clin Endocrinol (Oxf) 1975, 4:597-607.
18. Schlechte J.A. Clinical practice. Prolactinoma. N Engl J Med 2003, 349:2035-2041.
19. Schlechte J., Sherman B., Halmi N., et al. Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study. Endocr Rev 1980, 1:295-308.
20. Touraine P., Plu-Bureau G., Beji C., et al. Long-term follow-up of 246 hyperprolactinemic patients. Acta Obstet Gynecol Scand 2001, 80:162-168.
21. Carter J.N., Tyson J.E., Tolis G., et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978, 299:847-852.
22. Kunwar S., Wilson C.B. Pediatric pituitary adenomas. J Clin Endocrinol Metab 1999, 84:4385-4389.
23. Mindermann T., Wilson C.B. Pediatric pituitary adenomas. Neurosurgery 1995, 36:259-268. discussion 69.
24. Dyer E.H., Civit T., Visot A., et al. Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery 1994, 34:207-212. discussion 12.
25. Maira G., Anile C. Pituitary adenomas in childhood and adolescence. Can J Neurol Sci 1990, 17:83-87.
26. Shringi M.S., Vaidya R.A., Gogate J. Prolactin producing pituitary tumors in postmenopausal patients"infrequent or infrequently recognized". Fertil Steril 1998, 69:603-605.
27. Artese R., D'Osvaldo D.H., Molocznik I., et al. Pituitary tumors in adolescent patients. Neurol Res 1998, 20:415-417.
28. Colao A., Loche S., Cappa M., et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998, 83:2777-2780.
29. Duntas L.H. Prolactinomas in children and adolescents-consequences in adult life. J Pediatr Endocrinol Metab 2001, 14(suppl 5):1227-1232. discussion 61-2.
30. Minniti G., Jaffrain-Rea M.L., Ferretti E., et al. Macroprolactinomas as cause of delayed puberty. A report of two cases and effects of medical therapy. Minerva Endocrinol 1996, 21:67-71.
31. Jacobs H.S., Franks S., Murray M.A., et al. Clinical and endocrine features of hyperprolactinaemic amenorrhoea. Clin Endocrinol (Oxf) 1976, 5:439-454.
32. Greenspan S.L., Oppenheim D.S., Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989, 110:526-531.
33. Klibanski A., Greenspan S.L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986, 315:542-546.
34. Vartej P., Poiana C., Vartej I. Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 2001, 15:43-47.
35. Biller B.M., Baum H.B., Rosenthal D.I., et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992, 75:692-697.
36. Di Somma C., Colao A., Di Sarno A., et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998, 83:807-813.
37. Klibanski A., Biller B.M., Rosenthal D.I., et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988, 67:124-130.
38. Schlechte J., el-Khoury G., Kathol M., et al. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1987, 64:1021-1026.
39. Liu J.K., Couldwell W.T. Pituitary apoplexy: diagnosis and management. Contemp Neurosurg 2003, 25:1-6.
40. Liu J.K., Rovit R.L., Couldwell W.T. Pituitary apoplexy. Semin Neurosurg 2001, 12:315-320.
41. Liu J.K., Couldwell W.T. Contemporary management of prolactinomas. Neurosurg Focus 2004, 16(4):E2.
42. Molitch M.E. Diagnosis and treatment of prolactinomas. Adv Intern Med 1999, 44:117-153.
43. Comtois R., Robert F., Hardy J. Immunoradiometric assays may miss high prolactin levels. Ann Intern Med 1993, 119:173.
44. Barkan A.L., Chandler W.F. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": Case report. Neurosurgery 1998, 42:913-915. discussion 5-6.
45. Frieze T.W., Mong D.P., Koops M.K. "Hook effect" in prolactinomas: Case report and review of literature. Endocr Pract 2002, 8:296-303.
46. St-Jean E., Blain F., Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996, 44:305-309.
47. March C.M., Kletzky O.A., Davajan V., et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981, 139:835-844.
48. Schlechte J., Dolan K., Sherman B., et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989, 68:412-418.
49. Weiss M.H., Teal J., Gott P., et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983, 12:180-183.
50. Colao A., Annunziato L., Lombardi G. Treatment of prolactinomas. Ann Med 1998, 30:452-459.
51. Colao A., di Sarno A., Pivonello R., et al. Dopamine receptor agonists for treating prolactinomas. Exp Opin Investig Drugs 2002, 11:787-800.
52. Cunnah D., Besser M. Management of prolactinomas. Clin Endocrinol (Oxf) 1991, 34:231-235.
53. Weiss M.H., Wycoff R.R., Yadley R., et al. Bromocriptine treatment of prolactin-secreting tumors: surgical implications. Neurosurgery 1983, 12:640-642.
54. Ciccarelli E., Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996, 51:954-965.
55. Thorner M.O. Prolactinoma. West J Med 1983, 139:703-705.
56. Brue T., Pellegrini I., Priou A., et al. Prolactinomas and resistance to dopamine agonists. Horm Res 1992, 38:84-89.
57. Caccavelli L., Feron F., Morange I., et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994, 60:314-322.
58. Pellegrini I., Rasolonjanahary R., Gunz G., et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989, 69:500-509.
59. Colao A., Di Sarno A., Sarnacchiaro F., et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997, 82:876-883.
60. Couldwell W.T., Weiss M.H. Medical and surgical management of microprolactinoma. Pituitary 2004, 7:31-32.
61. Verhelst J.A. Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline. J Clin Endocrinol Metab 1999, 84:4747.
62. Colao A., Di Sarno A., Landi M.L., et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000, 85:2247-2252.
63. Thorner M.O., Perryman R.L., Rogol A.D., et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981, 53:480-483.
64. Zarate A., Canales E.S., Cano C., et al. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 1983, 104:139-142.
65. Orrego J.J., Chandler W.F., Barkan A.L. Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 2000, 3:189-192.
66. Couldwell W.T., Weiss M.H., Laws E.R. Prolactinomas. N Engl J Med 2004, 350:1054-1057. author reply 1054-1057.
67. Kars M., Pereira A.M., Smit J.W., et al. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 2009, 20:387-393.
68. Behan L.A., Draman M.S., Moran C., et al. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 2009.
69. Rasmussen C., Bergh T., Nillius S.J., et al. Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy. Fertil Steril 1985, 44:31-34.
70. Molitch M.E. Management of prolactinomas during pregnancy. J Reprod Med 1999, 44:1121-1126.
71. Robert E., Musatti L., Piscitelli G., et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996, 10:333-337.
72. Ricci E., Parazzini F., Motta T., et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002, 16:791-793.
73. Canales E.S., Garcia I.C., Ruiz J.E., et al. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 1981, 36:524-526.
74. van Roon E., van der Vijver J.C., Gerretsen G., et al. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril 1981, 36:173-177.
75. Konopka P., Raymond J.P., Merceron R.E., et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983, 146:935-938.
76. Bergh T., Nillius S.J., Enoksson P., et al. Bromocriptine-induced regression of a suprasellar extending prolactinoma during pregnancy. J Endocrinol Invest 1984, 7:133-136.
77. Molitch M.E. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985, 312:1364-1370.
78. Tyrrell J.B., Lamborn K.R., Hannegan L.T., et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999, 44:254-261. discussion 61-3.
79. Wilson C.B. Role of surgery in the management of pituitary tumors. Neurosurg Clin North Am 1990, 1:139-159.
80. Shrivastava R.K., Arginteanu M.S., King W.A., et al. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002, 97:299-306.
81. Wolfsberger S., Czech T., Vierhapper H., et al. Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir (Wien) 2003, 145:935-940. discussion 40-1.
82. Liuzzi A., Oppizzi G. Microprolactinomas: why requiem for surgery?. J Endocrinol Invest 1996, 19:196-198.
83. Peter S.A., Autz A., Jean-Simon M.L. Bromocriptine-induced schizophrenia. J Natl Med Assoc 1993, 85:700-701.
84. Liu J.K., Orlandi R.R., Apfelbaum R.I., et al. Novel closure technique for the endonasal transsphenoidal approach. Technical note. J Neurosurg 2004, 100:161-164.
85. Ciric I., Ragin A., Baumgartner C., et al. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997, 40:225-236. discussion 36-7.
86. Jane J.A., Thapar K., Kaptain G.J., et al. Pituitary surgery: transsphenoidal approach. Neurosurgery 2002, 51:435-442. discussion 42-4.
87. Kaptain G.J., Vincent D.A., Sheehan J.P., et al. Transsphenoidal approaches for the extracapsular resection of midline suprasellar and anterior cranial base lesions. Neurosurgery 2001, 49:94-100. discussion -1.
88. Liu J.K., Das K., Weiss M.H., et al. The history and evolution of transsphenoidal surgery. J Neurosurg 2001, 95:1083-1096.
89. Liu J.K., Weiss M.H., Couldwell W.T. Surgical approaches to pituitary tumors. Neurosurg Clin North Am 2003, 14:93-107.
90. Day J.D. Surgical approaches to suprasellar and parasellar tumors. Neurosurg Clin North Am 2003, 14(6):109-122.
91. Jane J.A., Han J., Prevedello D.M., et al. Perspectives on endoscopic transsphenoidal surgery. Neurosurg Focus 2005, 19(6):E2.
92. Landolt A.M. Surgical treatment of pituitary prolactinomas: postoperative prolactin and fertility in seventy patients. Fertil Steril 1981, 35:620-625.
93. Jane J.A., Laws E.R. The surgical management of pituitary adenomas in a series of 3,093 patients. J Am Coll Surg 2001, 193:651-659.
94. Randall R.V., Laws E.R., Abboud C.F., et al. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc 1983, 58:108-121.
95. Jho H.D., Carrau R.L. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 1997, 87:44-51.
96. Turner H.E., Adams C.B., Wass J.A. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?. Eur J Endocrinol 1999, 140:43-47.
97. Arnesen M., Scheithauer B.W. Aggressive small cell tumor of the skull base. Ultrastruct Pathol 1994, 18:191-197.
98. Bills D.C., Meyer F.B., Laws E.R., et al. A retrospective analysis of pituitary apoplexy. Neurosurgery 1993, 33:602-608. discussion 8-9.
99. Ebersold M.J., Laws E.R., Scheithauer B.W., et al. Pituitary apoplexy treated by transsphenoidal surgery. A clinicopathological and immunocytochemical study. J Neurosurg 1983, 58:315-320.
100. Laws E.R., Ebersold M.J. Pituitary apoplexy-an endocrine emergency. World J Surg 1982, 6:686-688.
101. Brisman M.H., Katz G., Post K.D. Symptoms of pituitary apoplexy rapidly reversed with bromocriptine. Case report. J Neurosurg 1996, 85:1153-1155.
102. Shin M. Gamma knife radiosurgery for pituitary adenoma. Biomed Pharmacother 2002, 56(suppl 1):178s-181s.
103. Ganz J.C. Gamma Knife treatment of pituitary adenomas. Stereotact Funct Neurosurg 1995, 64(suppl 1):3-10.
104. Ganz J.C., Backlund E.O., Thorsen F.A. The effects of gamma knife surgery of pituitary adenomas on tumor growth and endocrinopathies. Stereotact Funct Neurosurg 1993, 61(suppl 1):30-37.
105. Kim M.S., Lee S.I., Sim J.H. Gamma knife radiosurgery for functioning pituitary microadenoma. Stereotact Funct Neurosurg 1999, 72(suppl 1):119-124.
106. Kim S.H., Huh R., Chang J.W., et al. Gamma knife radiosurgery for functioning pituitary adenomas. Stereotact Funct Neurosurg 1999, 72(suppl 1):101-110.
107. Landolt A.M., Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurg 2000, 93(suppl 3):14-18.
108. Pan L., Zhang N., Wang E., et al. Pituitary adenomas: The effect of gamma knife radiosurgery on tumor growth and endocrinopathies. Stereotact Funct Neurosurg 1998, 70(suppl 1):119-126.
109. Pan L., Zhang N., Wang E.M., et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 2000, 93(suppl 3):10-13.
110. Pollock B.E., Nippoldt T.B., Stafford S.L., et al. Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg 2002, 97:525-530.
111. Castinetti F., Nagai M., Morange I., et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009, 94:3400-3407.
112. Jezkova J., Hana V., Krsek M., et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf) 2009, 70:732-741.
113. Couldwell W.T., Rosenow J.M., Rovit R.L., et al. Hypophysopexy technique for radiosurgical treatment of cavernous sinus pituitary adenoma. Pituitary 2002, 5:169-173.
114. Liu J.K., Schmidt M.H., MacDonald J.D., et al. Hypophysial transposition (hypophysopexy) for radiosurgical treatment of pituitary tumors involving the cavernous sinus: technical note. Neurosurg Focus 2003, 14(5). Article 11.
115. Amar A.P., Couldwell W.T., Chen J.C., et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 2002, 97:307-314.
116. Barkan A.L., Chandler W.F. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": Case report. Neurosurgery 1998, 42:913-915. discussion 915-916.
117. Colao A., Annunziato L., Lombardi G. Treatment of prolactinomas. Ann Med 1998, 30:452-459.
118. Colao A., Di Sarno A., Cappabianca P., et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003, 349:2023-2033.
119. Colao A., Di Sarno A., Landi M.L., et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000, 85:2247-2252.
120. Colao A., Di Sarno A., Sarnacchiaro F., et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997, 82:876-883.
121. Colao A., Loche S., Cappa M., et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998, 83:2777-2780.
122. Comtois R., Robert F., Hardy J. Immunoradiometric assays may miss high prolactin levels. Ann Intern Med 1993, 119:173.
123. Couldwell W.T., Rovit R.L., Weiss M.H. Role of surgery in the treatment of microprolactinomas. Neurosurg Clin North Am 2003, 14:89-92. vii.
124. Couldwell W.T., Weiss M.H. Medical and surgical management of microprolactinoma. Pituitary 2004, 7:31-32.
125. Landolt A.M., Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurg 2000, 93(suppl 3):14-18.
126. Liu J.K., Couldwell W.T. Contemporary management of prolactinomas. Neurosurg Focus 2004, 16:E2.
127. Molitch M.E. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002, 5:55-65.
128. Molitch M.E. Management of prolactinomas during pregnancy. J Reprod Med 1999, 44:1121-1126.
129. Molitch M.E. Diagnosis and treatment of prolactinomas. Adv Intern Med 1999, 44:117-153.
130. Nomikos P., Buchfelder M., Fahlbusch R. Current management of prolactinomas. J Neurooncol 2001, 54:139-150.
131. Schlechte J.A. Clinical practice. Prolactinoma. N Engl J Med 2003, 349:2035-2041.
132. Shrivastava R.K., Arginteanu M.S., King W.A., et al. Giant prolactinomas: Clinical management and long-term follow-up. J Neurosurg 2002, 97:299-306.
133. Thorner M.O., Perryman R.L., Rogol A.D., et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981, 53:480-483.
134. Turner T.H.E., Adams C.B., Wass J.A. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?. Eur J Endocrinol 1999, 140:43-47.
135. Tyrrell J.B., Lamborn K.R., Hannegan L.T., et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999, 44:254-261. discussion 261-263.
136. Vance M.L., Thorner M.O. Prolactinomas. Endocrinol Metab Clin North Am 1987, 16:731-753.
137. Wang M.Y., Weiss M.H. Is there a role for surgery for microprolactinomas?. Semin Neurosurg 2001, 12:289-294.
138. Weiss M.H., Teal J., Gott P., et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983, 12:180-183.
139. Weiss M.H., Wycoff R.R., Yadley R., et al. Bromocriptine treatment of prolactin-secreting tumors: Surgical implications. Neurosurgery 1983, 12:640-642.